This research report covers the global market for RNA sequencing. It incorporates an in-depth analysis of the RNA sequencing market, including market estimates and trends through 2029. For this analysis, the market has been segmented based on products, technologies, applications, end users and regions. In terms of geographical region, the market is divided into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). For market estimates, data has been provided for the base year 2023, with forecasts for 2024 through 2029.
Report Scope
This report also examines strategies and collaborations, discusses the regulatory landscape and analyzes macroeconomic factors when considering new technologies, the industry’s growing competition and changing customer needs. It also includes various analytical frameworks, such as ESG analysis, competitive analysis and strategic recommendations, that will help companies operating within this market devise their strategic plan of action.Report Includes
- 65 data tables and 57 additional tables
- A review of the global market and technologies for RNA sequencing
- Analyses of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Evaluation of the overall market for RNA sequencing, and corresponding market share analysis by product, technology, application, end-user and region
- Discussion of recent RNA sequencing approaches such as next-generation sequencing (NGS) technology, single nucleotide polymorphism (SNP) discovery, RNA editing, and Sanger sequencing technology
- Discussions of the market dynamics, opportunities and challenges, as well as emerging technologies
- Analysis of the regulatory landscape and macroeconomic factors impacting the market
- Coverage of the most recent approvals, recalls, safety alerts and clinical trials
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
- Competitive intelligence, including companies’ market shares, recent M&A activity and venture funding
- Profiles of the leading companies, including Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., and Qiagen
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Emerging Technologies and Developments
Chapter 5 Market Segmentation Analysis
Chapter 6 Competitive Intelligence
Chapter 7 Sustainability in RNA Sequencing Market: ESG Perspective
Chapter 8 Appendix
Company Profiles
Executive Summary
A novel technique in the genetic diagnostic lab, RNA sequencing, or RNA-Seq, is made feasible by the development of high-throughput, low-cost, next-generation sequencing technology. In the past, RNA research was restricted to measuring the expression of certain genes and detecting gene rearrangements using microarray technologies. A growing number of clinical samples are using RNA-Seq to detect qualitative and quantitative changes in RNA expression throughout the genome. It is being utilized as a supplement to whole-genome and diagnostic exome sequencing.RNA sequencing technology uses next-generation sequencing (NGS) to assess the continuously changing cellular transcriptome by revealing the presence and quantity of RNA in a biological sample at a certain time. It facilitates the examination of alternatively spliced transcripts, post-transcriptional modifications, gene fusion, mutations/SNPs and changes in gene expression over time, as well as variations in gene expression in different populations or therapeutic regimens. The RNA sequencing market is set to gain momentum due to the increasing adoption of NGS-based RNA technologies and products in various fields, including biomedical research and pharmaceutical development, coupled with increasing research investments, applications across multiple sectors and collaborative initiatives as well as acceleratingdevelopments in precision medicine.
Life sciences laboratories are increasingly shifting toward using high-throughput RNA sequencing as a standard method for transcript identification and differential gene expression research. Advances in next-generation sequencing (NGS) technology that have significantly reduced sequencing costs have made it possible for most scientists to afford to use this powerful approach. The final stage of an RNASeq experiment is data analysis. Here, selecting the appropriate software toolbox is essential to carrying out the required quality checks, resolving biases and, ultimately, providing answers to the study’s concerns. This enhances the accuracy of experimental results, leading to the significant adoption of such technologies in the market.
Companies Mentioned
- 10X GENOMICS
- AGILENT TECHNOLOGIES INC.
- BECKMAN COULTER INC. (SUBSIDIARY OF DANAHER CORP.)
- BIO-RAD LABORATORIES INC.
- BGI
- F. HOFFMANN-LA ROCHE LTD.
- ILLUMINA INC.
- INTEGRATED DNA TECHNOLOGIES INC.
- MICROSYNTH AG
- OXFORD NANOPORE TECHNOLOGIES PLC.
- QIAGEN
- REVVITY
- STANDARD BIOTOOLS
- THERMO FISHER SCIENTIFIC INC.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 166 |
| Published | September 2024 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value ( USD | $ 4.3 Billion |
| Forecasted Market Value ( USD | $ 10.3 Billion |
| Compound Annual Growth Rate | 19.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
